NCT06818279View on ClinicalTrials.gov

Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Portal Vein ThrombosisLiver Cirrhosis

Interventions

DRUG

Dabigatran

Dabigatran 150 mg BD fixed dose to be given for duration of 6 months.

DRUG

Enoxaparin

Enoxaparin . Treatment would be given with 1 mg /Kg (100IU/Kg) dose s/c twice daily for 6 months.

Trial Locations (1)

110070

Institute of Liver & Biliary Sciences (ILBS), New Delhi

All Listed Sponsors

lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT06818279 - Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis | Biotech Hunter | Biotech Hunter